gms | German Medical Science

Objectives: Up to 35% of periprosthetic infections (PJI) are thought to be caused by haematogenous spread. Since a clear-cut definition of haematogenous PJI and valid clinical data have been missing, the optimal therapeutic management is still controversial. Whereas several guidelines recommend theless invasive "debridement, antibiotics, and implant retention" (DAIR) strategyfor acute haematogenous PJI, some authors advocate a two- or multi-stage prosthesis exchange. Outcome of haematogenous periprosthetic joint infection (PJI) and reasons for failure are largely unknown

Methods: Outcome of consecutive patients with haematogenous PJI treated at our institution between 2010 and 2019 was evaluated. Failure was classified as persistence or relapse of infection or new infection. Failure-free survival was assessed using Kaplan-Meier analysis. Proportions between groups were compared with Fisher's exact test.

Results and conclusion: 132 haematogenous PJI episodes involving knee (n=76), hip (n=54), shoulder (n=1) or elbow (n=1) prostheses experienced by 110 patients were included. Median follow-up was 20.7 months (range, 0.2-89.9 months). Haematogenous PJI were caused by Staphylococcus aureus (n=49), Streptococcus spp. (n=36), Enterococcus faecalis (n=17), Enterobacterales (n=16), coagulase-negative staphylococci (n=9) and others (n=6). Debridement and implant retention were performed in 50 (38%), prosthesis exchange or removal in 79 (60%) and no surgery in 3 episodes (2%). Treatment failed in 42 episodes (32%), including 6 infection-related deaths. Among 36 non-fatal failures, 21 were caused by a new pathogen and 8 by the same pathogen, in 7 episodes no pathogen was isolated. Of all non-fatal failures, 19 (53%) PJI were of haematogenous origin. Identification of the primary focus, causative pathogen and CRIME80-Score did not influence treatment outcome, but failure rate was higher following prosthesis retention compared to multi-stage exchange.

In conclusion, persistence-/relapse-free survival after treatment of haematogenous PJI was high (84%). New haematogenous PJI due to the same or a new pathogen occurred frequently, reducing the treatment success to 62% after 4 years of follow-up, suggesting an individual predisposition to haematogenous PJI.